INTC vs PFE: Which Is the Better Buy?
Side-by-side comparison of Intel Corp. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-15.
Intel Corp. · Technology
$107.76
-5.2% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
INTC |
PFE |
| Current Price |
$107.76 |
$25.22 |
| Fair Value Estimate |
$102.16 |
$25.92 |
| Upside to Fair Value |
-5.2%
|
+2.8%
|
| Market Cap |
$541.6B |
$143.7B |
| Forward P/E |
-173.8x
|
19.2x
|
| EV / EBITDA |
49.9x
|
12.3x
|
| Price / Sales |
10.1x
|
2.3x
|
| Price / FCF |
-173.7x
|
15.2x
|
| Revenue Growth YoY |
+7.2%
|
+5.4%
|
| Gross Margin |
35.4%
|
69.3%
|
| Operating Margin |
-9.4%
|
23.4%
|
| Return on Equity |
-3.0%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Intel Corporation is a leading semiconductor company operating in the technology sector, specializing in designing and manufacturing microprocessors and related technologies. The business quality is currently low due to negative earnings growth of 354.1% in the most recent quarter and negative profitability metrics including a net margin of -5.9% and an operating margin of -9.4%. Despite a revenu…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
INTC |
PFE |
| Zone Low |
$76.62 |
$19.44 |
| Zone High |
$86.84 |
$22.03 |
| In Buy Zone? |
No
|
No
|